Mucinous adenocarcinoma of the prostate

Histochemical and immunohistochemical studies

Jae Y. Ro, David Grignon, Alberto G. Ayala, Pedro L. Fernandez, Nelson G. Ordonez, Kenneth I. Wishnow

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

Twelve patients with primary mucinous adenocarcinoma of the prostate were included in a clinicopathologic study; criteria included a total tumor volume more than 25% mucinous and single or clustered tumor cells floating in mucin lakes. Patient ages were 57 to 81 years; tumor stages were C (three), D (five), and unknown (four). Bone was the most frequent metastatic site (usually osteoblastic), followed by lumph nodes and lungs. Serum levels of prostatic acid phosphatase and prostate-specific antigen were frequently elevated (five of 10 and three of three measured, respectively). All mucinous adenocarcinomas also contained other histologic patterns: microglandular (four), cribriform (three), comedo (two), solid (two), and hypernephroid (one). Mucinous components composed less than 50% of three tumors, 50% and 75% of six, and more than 75% of three. No tumor contained signet-ring cells. Immunoperoxidase staining was positive for prostatic acid phosphatase and prostate-specific antigen and negative for carcinoembryonic antigen. Treatment was radiation, estrogen, orchiectomy, or a combination. In two of four patients, serum prostatic acid phosphatase levels normalized after therapy. Seven patients died of disease (mean follow-up, 56 months), and five patients are alive with disease (mean, 32.2 months). The proportion of mucinous component did not affect prognosis.

Original languageEnglish (US)
Pages (from-to)593-600
Number of pages8
JournalHuman Pathology
Volume21
Issue number6
DOIs
StatePublished - 1990
Externally publishedYes

Fingerprint

Mucinous Adenocarcinoma
Prostate
Prostate-Specific Antigen
Neoplasms
Orchiectomy
Carcinoembryonic Antigen
Mucins
Lakes
Tumor Burden
Serum
Estrogens
Radiation
Staining and Labeling
Bone and Bones
Lung
Therapeutics
prostatic acid phosphatase

Keywords

  • mucin lakes
  • mucinous adenocarcinoma
  • prostate
  • prostate-specific antigen
  • prostatic acid phosphatase

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Mucinous adenocarcinoma of the prostate : Histochemical and immunohistochemical studies. / Ro, Jae Y.; Grignon, David; Ayala, Alberto G.; Fernandez, Pedro L.; Ordonez, Nelson G.; Wishnow, Kenneth I.

In: Human Pathology, Vol. 21, No. 6, 1990, p. 593-600.

Research output: Contribution to journalArticle

Ro, Jae Y. ; Grignon, David ; Ayala, Alberto G. ; Fernandez, Pedro L. ; Ordonez, Nelson G. ; Wishnow, Kenneth I. / Mucinous adenocarcinoma of the prostate : Histochemical and immunohistochemical studies. In: Human Pathology. 1990 ; Vol. 21, No. 6. pp. 593-600.
@article{58c1f17a6f9645e0b1bf997029c26d75,
title = "Mucinous adenocarcinoma of the prostate: Histochemical and immunohistochemical studies",
abstract = "Twelve patients with primary mucinous adenocarcinoma of the prostate were included in a clinicopathologic study; criteria included a total tumor volume more than 25{\%} mucinous and single or clustered tumor cells floating in mucin lakes. Patient ages were 57 to 81 years; tumor stages were C (three), D (five), and unknown (four). Bone was the most frequent metastatic site (usually osteoblastic), followed by lumph nodes and lungs. Serum levels of prostatic acid phosphatase and prostate-specific antigen were frequently elevated (five of 10 and three of three measured, respectively). All mucinous adenocarcinomas also contained other histologic patterns: microglandular (four), cribriform (three), comedo (two), solid (two), and hypernephroid (one). Mucinous components composed less than 50{\%} of three tumors, 50{\%} and 75{\%} of six, and more than 75{\%} of three. No tumor contained signet-ring cells. Immunoperoxidase staining was positive for prostatic acid phosphatase and prostate-specific antigen and negative for carcinoembryonic antigen. Treatment was radiation, estrogen, orchiectomy, or a combination. In two of four patients, serum prostatic acid phosphatase levels normalized after therapy. Seven patients died of disease (mean follow-up, 56 months), and five patients are alive with disease (mean, 32.2 months). The proportion of mucinous component did not affect prognosis.",
keywords = "mucin lakes, mucinous adenocarcinoma, prostate, prostate-specific antigen, prostatic acid phosphatase",
author = "Ro, {Jae Y.} and David Grignon and Ayala, {Alberto G.} and Fernandez, {Pedro L.} and Ordonez, {Nelson G.} and Wishnow, {Kenneth I.}",
year = "1990",
doi = "10.1016/S0046-8177(96)90004-0",
language = "English (US)",
volume = "21",
pages = "593--600",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",
number = "6",

}

TY - JOUR

T1 - Mucinous adenocarcinoma of the prostate

T2 - Histochemical and immunohistochemical studies

AU - Ro, Jae Y.

AU - Grignon, David

AU - Ayala, Alberto G.

AU - Fernandez, Pedro L.

AU - Ordonez, Nelson G.

AU - Wishnow, Kenneth I.

PY - 1990

Y1 - 1990

N2 - Twelve patients with primary mucinous adenocarcinoma of the prostate were included in a clinicopathologic study; criteria included a total tumor volume more than 25% mucinous and single or clustered tumor cells floating in mucin lakes. Patient ages were 57 to 81 years; tumor stages were C (three), D (five), and unknown (four). Bone was the most frequent metastatic site (usually osteoblastic), followed by lumph nodes and lungs. Serum levels of prostatic acid phosphatase and prostate-specific antigen were frequently elevated (five of 10 and three of three measured, respectively). All mucinous adenocarcinomas also contained other histologic patterns: microglandular (four), cribriform (three), comedo (two), solid (two), and hypernephroid (one). Mucinous components composed less than 50% of three tumors, 50% and 75% of six, and more than 75% of three. No tumor contained signet-ring cells. Immunoperoxidase staining was positive for prostatic acid phosphatase and prostate-specific antigen and negative for carcinoembryonic antigen. Treatment was radiation, estrogen, orchiectomy, or a combination. In two of four patients, serum prostatic acid phosphatase levels normalized after therapy. Seven patients died of disease (mean follow-up, 56 months), and five patients are alive with disease (mean, 32.2 months). The proportion of mucinous component did not affect prognosis.

AB - Twelve patients with primary mucinous adenocarcinoma of the prostate were included in a clinicopathologic study; criteria included a total tumor volume more than 25% mucinous and single or clustered tumor cells floating in mucin lakes. Patient ages were 57 to 81 years; tumor stages were C (three), D (five), and unknown (four). Bone was the most frequent metastatic site (usually osteoblastic), followed by lumph nodes and lungs. Serum levels of prostatic acid phosphatase and prostate-specific antigen were frequently elevated (five of 10 and three of three measured, respectively). All mucinous adenocarcinomas also contained other histologic patterns: microglandular (four), cribriform (three), comedo (two), solid (two), and hypernephroid (one). Mucinous components composed less than 50% of three tumors, 50% and 75% of six, and more than 75% of three. No tumor contained signet-ring cells. Immunoperoxidase staining was positive for prostatic acid phosphatase and prostate-specific antigen and negative for carcinoembryonic antigen. Treatment was radiation, estrogen, orchiectomy, or a combination. In two of four patients, serum prostatic acid phosphatase levels normalized after therapy. Seven patients died of disease (mean follow-up, 56 months), and five patients are alive with disease (mean, 32.2 months). The proportion of mucinous component did not affect prognosis.

KW - mucin lakes

KW - mucinous adenocarcinoma

KW - prostate

KW - prostate-specific antigen

KW - prostatic acid phosphatase

UR - http://www.scopus.com/inward/record.url?scp=0025360114&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025360114&partnerID=8YFLogxK

U2 - 10.1016/S0046-8177(96)90004-0

DO - 10.1016/S0046-8177(96)90004-0

M3 - Article

VL - 21

SP - 593

EP - 600

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

IS - 6

ER -